Clinical stage I and II Hodgkin's disease : Long-term results of therapy without laparotomy : Experience at one institution

We concluded a program in which we administered radiotherapy only to clinical stages I and II Hodgkin's disease patients at standard risk, with the addition of 4 cycles of combination chemotherapy before radiotherapy for high-risk patients. From 1980 to 1991, 313 patients with clinical stages I...

Full description

Saved in:

Bibliographic Details
Published in:	Annals of oncology Vol. 7; no. 2; pp. 145 - 150
Main Authors:	FOSS ABRAHAMSEN, A, HANNISDAL, E, NOME, O, HOLTE, H, HAGER, B, LANGHOLM, R, KVALY, S
Format:	Journal Article
Language:	English
Published:	Oxford Oxford University Press 01-02-1996
Subjects:	Adolescent Adult Age Factors Aged Antineoplastic agents Antineoplastic Agents - therapeutic use Biological and medical sciences Chemotherapy Disease-Free Survival Female Follow-Up Studies Hodgkin Disease - drug therapy Hodgkin Disease - mortality Hodgkin Disease - pathology Hodgkin Disease - radiotherapy Humans Laparotomy Male Medical sciences Middle Aged Neoplasm Staging Pharmacology. Drug treatments Radiotherapy Dosage Risk Factors Antineoplastic agent Human Relapse Adjuvant treatment Hodgkin disease Early stage Malignant hemopathy Radiotherapy Lymphoma Long term Chemotherapy Clinical stage Lymphoproliferative syndrome Combined treatment
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	We concluded a program in which we administered radiotherapy only to clinical stages I and II Hodgkin's disease patients at standard risk, with the addition of 4 cycles of combination chemotherapy before radiotherapy for high-risk patients. From 1980 to 1991, 313 patients with clinical stages I or II Hodgkin's disease underwent treatment in our hospital. Fifty percent of the patients in groups previously identified as being at high risk for relapse received 4 cycles of combination chemotherapy before radiotherapy. The remaining half of the patients received radiotherapy only. Low- and high-risk patients aged 15-59 years had, respectively, complete remission (CR) rates of 97% and 94%, 5-year survivals of 95% and 91%, and 5-year freedom from relapse (FFR) rates of 78% and 89%. Older low- and high-risk groups had CR rates of 97% and 93%, 5-year survivals of 60% and 56% and 5-year FFR of 77% and 93%, respectively. Here we present our favorable results after treating standard-risk patients with clinical stages I and II Hodgkin's disease with radiotherapy only. With the addition of chemotherapy, the rate of relapse in the high-risk patients was reduced below that of the standard-risk patients. Overall survival was the same for the high- and standard-risk patients.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23
ISSN:	0923-7534 1569-8041